Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752687 | 1.00 | KMT2A (0.51) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL29624572 | 1.00 | KMT2A (0.51) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL30594472 | 0.97 | KMT2A (0.51) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL29624557 | 0.97 | KMT2A (0.51) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL178775 | 0.97 | KMT2A (0.51) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL30594467 | 0.96 | KMT2A (0.50) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL29624551 | 0.96 | KMT2A (0.50) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL29624561 | 0.96 | KMT2A (0.50) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL7401413 | 0.96 | KMT2A (0.50) | KMT2AEPHX2DPP8DPP9FABP5 | |
| SCHEMBL178786 | 0.96 | KMT2A (0.50) | KMT2AEPHX2DPP8DPP9FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025098422-A1 | MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20110136697-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | KARUS THERAPEUTICS LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| US-7935658-B2 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2293846-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | Karus Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009141658-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| US-20090062147-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1822/4885EPHX2 3517/4885DPP8 1645/4885 |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | FKBP1B, FKBP5, FKBP1A | KMT2A 1826/4885EPHX2 4481/4885DPP8 3987/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | KMT2A 4757/4885EPHX2 3088/4885DPP8 177/4885 |
| US-20230295221-A1 | EFFICIENT PEPTIDE CONDENSATION METHOD FOR DIFFICULT SEQUENCES | NGLY1, VIP, DNPEP | KMT2A 3727/4885EPHX2 3850/4885DPP8 888/4885 |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | PRLHR, OPRD1, NPR3 | KMT2A 4643/4885EPHX2 3625/4885DPP8 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.